Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer

Breast Cancer Research : BCR
Laura A BakerAlexander Swarbrick

Abstract

Basal-like breast cancer (BLBC) is a poorly characterised, heterogeneous disease. Patients are diagnosed with aggressive, high-grade tumours and often relapse with chemotherapy resistance. Detailed understanding of the molecular underpinnings of this disease is essential to the development of personalised therapeutic strategies. Inhibitor of differentiation 4 (ID4) is a helix-loop-helix transcriptional regulator required for mammary gland development. ID4 is overexpressed in a subset of BLBC patients, associating with a stem-like poor prognosis phenotype, and is necessary for the growth of cell line models of BLBC through unknown mechanisms. Here, we have defined unique molecular insights into the function of ID4 in BLBC and the related disease high-grade serous ovarian cancer (HGSOC), by combining RIME proteomic analysis, ChIP-seq mapping of genomic binding sites and RNA-seq. These studies reveal novel interactions with DNA damage response proteins, in particular, mediator of DNA damage checkpoint protein 1 (MDC1). Through MDC1, ID4 interacts with other DNA repair proteins (γH2AX and BRCA1) at fragile chromatin sites. ID4 does not affect transcription at these sites, instead binding to chromatin following DNA damage. Analysis ...Continue Reading

References

Nov 1, 1996·Developmental Dynamics : an Official Publication of the American Association of Anatomists·Y JenR Benezra
Aug 8, 1997·The Journal of Biological Chemistry·K LanglandsE V Prochownik
Aug 30, 2000·Nature·C M PerouD Botstein
Jan 3, 2001·Molecular and Cellular Biology·E C RobertsA D Sharrocks
Jan 3, 2001·Proceedings of the National Academy of Sciences of the United States of America·C BegerF Wong-Staal
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Mar 22, 2002·Nature Reviews. Immunology·I Engel, C Murre
Jun 5, 2002·Genome Research·W James KentDavid Haussler
Feb 28, 2003·Nature·Grant S StewartStephen J Elledge
Jul 31, 2003·Trends in Cell Biology·Marianna B Ruzinova, Robert Benezra
Nov 25, 2003·The American Journal of Pathology·Liang ShanElizabeth G Snyderwine
May 15, 2004·The Biochemical Journal·Kei TakenakaHiroaki Miki
Jul 29, 2004·Cancer Biology & Therapy·Ralph ScullyGanesh Nagaraju
Jun 22, 2005·Proceedings of the National Academy of Sciences of the United States of America·Saori FurutaWen-Hwa Lee
Jul 13, 2005·The Journal of Cell Biology·Simon Bekker-JensenJiri Lukas
Dec 7, 2005·The Journal of Cell Biology·Kevin WilhelmsenArnoud Sonnenberg
Apr 4, 2006·Cancer Biology & Therapy·Gloria RoldánIgnacio Miguel Musé
Sep 15, 2006·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Jan H SchefeHeiko Funke-Kaiser
Oct 4, 2006·Oncogene·N C TurnerA N Tutt
Mar 24, 2007·Bioinformatics·Triinu Koressaar, Maido Remm
Oct 9, 2007·Nature Genetics·Miguel Angel PujanaMarc Vidal
Sep 2, 2008·The Journal of Biological Chemistry·Wei ShiJunran Zhang
Sep 19, 2008·Genome Biology·Yong ZhangX Shirley Liu
Mar 12, 2009·Methods : a Companion to Methods in Enzymology·Dominic SchmidtDuncan T Odom
Jun 10, 2009·Bioinformatics·Heng LiUNKNOWN 1000 Genome Project Data Processing Subgroup
Sep 29, 2009·Nature Structural & Molecular Biology·Giulia FontemaggiGiovanni Blandino
Oct 15, 2009·The Journal of Biological Chemistry·Kelly TownsendGrant S Stewart
Jun 16, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Panagiotis A KonstantinopoulosStephen A Cannistra
Dec 8, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M A VolleberghS C Linn
Jan 12, 2011·Nature Biotechnology·James T RobinsonJill P Mesirov
May 10, 2011·Molecular Cancer Research : MCR·Kathleen A WilsonDavid F Stern
Jul 2, 2011·Nature·UNKNOWN Cancer Genome Atlas Research Network
Oct 12, 2011·Proceedings of the National Academy of Sciences of the United States of America·Hiroyuki KonishiBen Ho Park
Nov 26, 2011·Gynecologic Oncology·Céline MontavonPhilippa M O'Brien
Dec 14, 2011·Cell·Phillippa C TaberlayPeter A Jones
Mar 6, 2012·Nature Methods·Ben Langmead, Steven L Salzberg

❮ Previous
Next ❯

Citations

Oct 14, 2020·Translational Oncology·Vinitha RichardRadhakrishna M Pillai

❮ Previous
Next ❯

Methods Mentioned

BETA
Protein Assay
immunoprecipitation
ChIP-exo
electrophoresis
xenograft
chip
PCR
xenografts
proximity ligation
proximity ligation assay

Software Mentioned

MACS
Gene Set Enrichment Analysis ( GSEA
FIJI
ImageJ
Bowtie for Illumina
FastQC
SDS
Primer3
Sam
cutadapt

Related Concepts

Related Feeds

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.